Neelima Vidula, MD, Massachusetts General Hospital, Boston, MA, tells us more about how age-specific variations in immune-related adverse events (irAEs) might influence the management and monitoring of older patients on immunotherapy. Additionally, Dr Vidula notes the specific considerations for toxicity management in the elderly population that should be taken into account. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.